Sub-$1 stocks get dismissed as lottery tickets, but the ten names on this list all have something most penny stocks don’t: a real, dated, verifiable catalyst. A truck-accessory maker just posted seven straight months of record sales. A bioengineered blood vessel company has an FDA supplemental filing due in November. A Chinese insurtech grew revenue 41% while most of its peers were shrinking. None of these are the meme-stock, no-news-explains-the-move type of penny plays — every name below has a specific reason analysts and traders are watching it heading into Monday’s session.

A Word on Risk Before We Start:

Every stock on this list trades under $1 for a reason — thin float, heavy historical dilution, or a business still working to prove itself. These are genuinely high-risk, high-volatility securities. Position sizing and independent due diligence matter far more here than with any large-cap name.

Stocks Under $1 to Watch Tomorrow: Sept 21, 2026:

1. Worksport Ltd. (WKSP) | Last Price $0.43

A Truck Cover Maker’s Seven-Month Sales Streak Nobody’s Talking About

Worksport has posted increasing monthly net sales for seven straight months through July 2026, averaging roughly 12.9% month-over-month growth over the last five, with preliminary gross margins holding above 30% for a third consecutive month.

Full Data & Technical Snapshot:

Why Watch It: Worksport regained Nasdaq’s $1 minimum bid price compliance earlier this year and has since posted record July orders of $2.5 million, with CEO commentary explicitly stating the current market valuation “does not yet fully reflect” the company’s operating progress toward cash-flow positivity — a message reinforced by continued insider buying from the founder.

Bull Case: Seven consecutive months of sales growth is a genuinely rare data point for a sub-$1 stock, and a 58% reduction in Q2 operating cash use alongside a 32% narrower net loss both point to a company closing the gap toward profitability rather than simply burning cash.

Bear Case: The stock has fallen from over $9 to under $0.50 over the trailing year, reflecting a long history of shareholder dilution through warrant inducements and direct offerings — a pattern that has repeatedly capped rallies in the past.

Forecast: A sustained close back above $1.00 would remove the renewed Nasdaq compliance overhang entirely; continued month-over-month sales acceleration into Q3 is the clearest fundamental signal to track.

Why This Matters: Worksport is a rare case of a sub-$1 stock with genuinely improving unit economics — the kind of story that can re-rate quickly if the sales trend continues without another dilutive raise.

2. AEON Biopharma (AEON) | Last Price $0.25

A Botox Competitor Just Got Its Third Buy Rating in Two Months

AEON Biopharma was initiated with a Buy rating at Laidlaw on September 9, its second fresh Buy initiation in as many months, following Lake Street’s July 30 Buy call on the company’s botulinum toxin candidate ABP-450 as a potential Botox competitor.

Full Data & Technical Snapshot:

Why Watch It: Despite H.C. Wainwright trimming its price target sharply from $5 to $1.20 in August, the firm maintains its underlying thesis on ABP-450’s competitive positioning, and the stock has now attracted two separate fresh Buy initiations within six weeks — an unusual concentration of bullish analyst attention for a $12.7 million market cap name.

Bull Case: Even the reduced $1.20 price target implies roughly 4x upside from current levels, and AEON’s regains of NYSE American listing compliance combined with a newly designated acting chief regulatory officer suggest the company is actively shoring up both its financial and regulatory footing.

Bear Case: A 975% surge in short interest over the past year signals genuine, organized bearish conviction, and a company that has repeatedly turned to dilutive share sales (including a $13.75 million offering in July) to fund operations faces an uphill battle to avoid further shareholder dilution.

Forecast: Full results from the ABP-450 pilot forced degradation study, and any follow-through analyst commentary on the Laidlaw initiation, are the most immediate catalysts that could move the stock in either direction this week.

Why This Matters: AEON is a high-risk, binary biotech bet — but the clustering of fresh analyst coverage in a stock this small is a signal worth tracking regardless of whether you’d actually trade it.

3. Zhibao Technology (ZBAO) | Last Price $0.25

A Chinese InsurTech Growing Revenue 41% While Trading Like It’s Going Out of Business

Zhibao Technology reported first-half 2026 revenue of RMB 206 million (approximately $29.5 million), up 41% from RMB 146.4 million a year earlier, even as the stock itself trades near its 52-week low.

Full Data & Technical Snapshot:

Why Watch It: Beyond the headline revenue growth, Zhibao has been aggressively diversifying its insurance product lineup — partnering with Sichuan Fanmo Technology to launch specialized insurance for individual drone pilots, and reporting that natural gas insurance premiums are approaching RMB 100 million, a 10x increase from 2025, pointing to genuine new-market expansion rather than one-off growth.

Bull Case: A 41% revenue growth rate paired with a market cap of just $22 million implies an extremely low price-to-sales ratio for a company that swung to profitability in its latest half-year period — a disconnect that value-focused penny stock investors specifically look for.

Bear Case: Zhibao received a Nasdaq compliance notice in mid-2026, and as a small-float Chinese ADR-style listing, the stock carries the added layers of regulatory and currency risk common to U.S.-listed Chinese micro-caps, on top of standard penny-stock volatility.

Forecast: Continued disclosure of new B-end partnerships (drone insurance, natural gas insurance) at the current pace would reinforce the diversification thesis; any resolution of the Nasdaq compliance matter would remove a real overhang on the stock.

Why This Matters: Zhibao is one of the more fundamentally-grounded names on this list — real, audited revenue growth in a stock priced like it has none, which is exactly the kind of mismatch penny stock screens are built to surface.

4. Armlogi Holding (BTOC) | Last Price $0.28–$0.30

A Logistics Company With Earnings Landing This Week

Armlogi Holding, a U.S.-based warehousing and logistics provider for cross-border e-commerce merchants, reported Q2 revenue of $51.5 million, roughly flat against $51.1 million a year earlier, and is scheduled to report its next quarterly results around September 25, 2026 — just days after this watchlist’s publication.

Full Data & Technical Snapshot:

Why Watch It: Armlogi recently launched an AI-enabled Smart Fulfillment Network designed to dynamically optimize order routing across its multi-state warehouse footprint, a genuine operational upgrade landing right before its next earnings report — giving the stock a concrete, dated catalyst in the immediate term.

Bull Case: Stable revenue in a difficult cross-border e-commerce logistics environment, combined with a full repayment of prior debt obligations to its Standby Equity Purchase Agreement partner, suggests Armlogi has stabilized its balance sheet heading into the print.

Bear Case: The stock has fallen from $4.15 to under $0.30 over the trailing year — an 83%+ decline — and a prior quarter’s earnings miss (a $0.13 per-share loss against a $0.04 estimate) shows the company’s execution has been inconsistent even as revenue holds roughly flat.

Forecast: With earnings landing just days out, expect elevated volatility into and through the report — a beat that shows the Smart Fulfillment Network genuinely improving margins would be the clearest bullish confirmation.

Why This Matters: Armlogi’s imminent earnings date makes it the most time-sensitive name on this list — whatever direction the stock breaks post-earnings is likely to happen fast, given its thin float and history of double-digit single-day swings.

5. Traws Pharma (TRAW) | Last Price $0.53–$0.57

An Antiviral Biotech Betting on the Next Pandemic Threat

Traws Pharma, a clinical-stage biopharmaceutical company developing oral antiviral therapies against COVID-19, Long COVID, bird flu, and seasonal influenza, closed at $0.5315 on September 10, down 71% over the trailing 12 months.

Full Data & Technical Snapshot:

Why Watch It: Traws integrates antiviral drug development with medical intelligence and regulatory strategy, specifically targeting virus strains resistant to existing treatment options — a differentiated positioning in a biotech sector that has seen renewed interest in pandemic-preparedness names given ongoing bird flu concerns in agricultural sectors.

Bull Case: A 9.5% institutional stake from Ikarian Capital, disclosed via a recent 13G/A filing, signals continued sophisticated investor interest even as the broader stock has been battered, and any positive clinical trial readout on its oral small-molecule candidates could trigger a sharp re-rating from current depressed levels.

Bear Case: A 71% one-year decline reflects genuine, sustained investor disappointment rather than a temporary dip, and clinical-stage biotechs at this market cap face constant dilution risk through private placements to fund ongoing trials.

Forecast: Watch for any updates tied to Traws’ active clinical programs or additional institutional filings — a stock this beaten-down typically needs a specific, dated catalyst rather than general sentiment to reverse trend.

Why This Matters: Traws represents the higher-risk end of this list — a true clinical-stage biotech where the stock price reflects genuine skepticism about near-term commercial viability, balanced against real institutional conviction from at least one sophisticated holder.

6. Humacyte (HUMA) | Last Price $0.59

An FDA-Approved Product With a November Regulatory Deadline

Humacyte’s Symvess — the first and only FDA-approved bioengineered human blood vessel — is expanding from trauma use into dialysis access and cardiovascular markets, with a supplemental Biologic License Application for dialysis access planned for November 2026.

Full Data & Technical Snapshot:

Why Watch It: A Phase 3 V012 dialysis access study showed Humacyte’s ATEV product outperforming the standard-of-care AV fistula, and the company is simultaneously expanding Symvess adoption geographically — a Mayo Clinic-trained vascular surgeon in Phoenix recently became the first in Arizona to implant the device, evidence of genuine on-the-ground commercial traction beyond clinical trial headlines.

Bull Case: With five analysts carrying an average Buy rating and a price target implying over 200% upside from current levels, combined with an already-approved, revenue-generating product and cash runway extending into late 2027, Humacyte has more de-risked fundamentals than most sub-$1 biotechs.

Bear Case: A $36.8 million net loss and persistent cash burn mean Humacyte will likely need to raise additional capital before reaching sustainable profitability, and the stock’s fall below $1 has already triggered Nasdaq compliance concerns that could pressure shares further if not resolved.

Forecast: The November 2026 supplemental BLA filing for dialysis access is the single most concrete near-term catalyst on this entire list — a successful filing meaningfully expands Symvess’s addressable market beyond trauma indications.

Why This Matters: Humacyte stands out for having an FDA-approved, commercially available product generating real (if still small) revenue — a meaningfully lower speculative bar to clear than most names on a sub-$1 watchlist.

7. SOS Limited (SOS) | Last Price $0.66

A Volatility Machine With Fresh Capital and a New Investor Group

SOS Limited swung within a wide $0.56-to-$1.05 intraday range on September 19 on volume of 5.12 million shares — more than nine times its 559,570-share average, a day after entering a securities purchase agreement with a group of non-U.S. investors.

Full Data & Technical Snapshot:

Why Watch It: SOS has repositioned itself over the years from emergency rescue services into Bitcoin and Ethereum mining operations, and the September 18 securities purchase agreement with non-U.S. institutional investors — details of which weren’t fully disclosed at announcement — is the kind of capital-raise headline that has historically produced dramatic single-day swings in this specific stock.

Bull Case: A history of massive percentage moves on capital-raise and crypto-mining-related news (the stock once surged nearly 60% in a single session on a single earnings report) means SOS has genuine event-driven volatility that active traders specifically seek out.

Bear Case: A company with negative EBITDA of roughly $90 million and a history of dramatic reverse-fortune swings between rescue services, crypto mining, and other pivots represents one of the more speculative, narrative-driven names on this entire list.

Forecast: Full terms of the September 18 securities purchase agreement, once disclosed, will likely determine whether this week’s elevated volume and volatility continues or fades — dilution terms specifically will be the key detail to watch.

Why This Matters: SOS is the purest “trader’s stock” on this list — a name with genuine liquidity and volatility, but correspondingly higher risk given its history of business-model pivots and capital raises.

8. Ryde Group (RYDE) | Last Price $0.71

Singapore’s Carpooling App Signs an Autonomous Vehicle Deal

Ryde Group, Singapore’s homegrown carpooling and quick-commerce platform, entered a Memorandum of Understanding with UISEE Technologies to explore strategic collaboration on autonomous vehicle projects in Singapore.

Full Data & Technical Snapshot:

Why Watch It: The UISEE partnership positions Ryde at the intersection of two structural growth themes — Southeast Asian mobility demand and the broader global push toward autonomous vehicle deployment — giving the stock a narrative catalyst beyond its core ride-hailing and delivery business.

Bull Case: A $118 million market cap against a 52-week high of $1.55 (more than double the current price) suggests real recovery room if the autonomous vehicle collaboration progresses from MOU to actual deployment, and Ryde’s dual Mobility and Quick Commerce segments provide revenue diversification most single-line-of-business penny stocks lack.

Bear Case: MOUs are non-binding exploratory agreements, not confirmed commercial deals, and the gap between “exploring strategic collaboration” and actual revenue-generating autonomous vehicle operations in a tightly regulated market like Singapore could be measured in years, not months.

Forecast: Any follow-up disclosure converting the UISEE MOU into a definitive agreement, pilot program, or specific deployment timeline would be the clearest signal the partnership is progressing beyond a press-release-only stage.

Why This Matters: Ryde offers geographic and thematic diversification from the U.S.-centric names dominating most penny stock lists — a genuine Southeast Asian mobility play with a speculative but real AV angle attached.

9. Nuwellis (NUWE) | Last Price ~$0.71–$1.00

A Medtech Stock That Hit an All-Time Low the Same Week Revenue Grew

Nuwellis touched an all-time low of $0.7112 on September 3, 2026, even as the cardiorenal medical device company reported preliminary revenue growth of 14% year-over-year for Q2 2026 and 20% for the first half, driven by continued adoption of its Aquadex ultrafiltration platform.

Full Data & Technical Snapshot:

Why Watch It: Nuwellis received U.S. Patent No. 12,678,592 for its Dual Lumen Catheter design and is pursuing FDA label expansion for pediatric patients as young as 5 kilograms — a genuine addressable-market expansion opportunity for a company whose core Aquadex platform is already commercially sold.

Bull Case: Revenue growth of 14–20% at a company trading with a market cap under $3.5 million represents an extreme valuation disconnect, and a newly issued patent plus an active FDA pediatric submission both represent concrete, dated catalysts rather than speculative narrative alone.

Bear Case: A 22.4% short interest as a percentage of float — up more than 300% year-over-year — signals significant organized bearish conviction, and the stock’s extraordinary volatility (a run from roughly $3 to $6.40 and back down to under $1 within a matter of weeks this summer) makes it one of the riskiest names on this entire list.

Forecast: The pediatric label expansion submission, expected sometime between September and December 2026, is the single clearest near-term catalyst — any FDA acceptance or fast-track designation would be a meaningful positive data point.

Why This Matters: Nuwellis is a genuine battleground stock — real revenue growth and patent-protected technology colliding with heavy short interest and extreme volatility, making it a name to watch rather than one to approach casually.

10. QTREX Quantum, formerly Inspira Technologies (QTEX) | Last Price ~$0.40–$0.50

A Medtech Company’s Surprising Pivot Into Quantum Connectivity

Formerly known as Inspira Technologies and trading under ticker IINN, the company rebranded to QTREX Quantum (Nasdaq: QTEX) in May 2026 as it expanded beyond its original respiratory support and blood monitoring medtech business into additively manufactured electronics and quantum connectivity technology.

Full Data & Technical Snapshot:

Why Watch It: One of Israel’s three largest defense companies began immediate deployment of QTREX Quantum’s additively manufactured electronics (AME) technology in early September, while the company’s original medical device business — including the FDA-cleared INSPIRA ART100 respiratory support system — continues operating as a separate, dedicated unit.

Bull Case: A defense-sector deployment with one of Israel’s largest defense contractors represents genuine commercial validation of the quantum connectivity pivot, and maintaining the legacy FDA-cleared medical device business provides a revenue floor while the newer AME and quantum segments scale.

Bear Case: Ticker and strategic pivots of this magnitude often signal a company still searching for a sustainable business model, and the $10 million August capital raise adds to a long history of dilutive financings that have repeatedly pressured the stock toward its current sub-$1 levels.

Forecast: Continued disclosure of specific deployment milestones with the Israeli defense partner, along with any update on the medical device segment’s standalone performance, will be the key data points determining whether the quantum pivot is gaining real commercial traction.

Why This Matters: QTREX Quantum’s dual identity — an FDA-cleared medtech company simultaneously deploying quantum connectivity hardware with a major defense contractor — makes it one of the more unusual, genuinely differentiated stories on this list.

Sector Sentiment Snapshot & Forecast

This week’s sub-$1 watchlist splits into three loose categories. Genuine operational improvement stories (Worksport, Zhibao Technology, Armlogi) show real revenue growth or narrowing losses trading at valuations that don’t yet reflect that progress — the classic penny-stock value setup. Binary biotech and medtech catalysts (AEON Biopharma, Traws Pharma, Humacyte, Nuwellis) each carry a specific, dated regulatory or clinical event that could move shares sharply in either direction. And high-volatility, narrative-driven names (SOS Limited, Ryde Group, QTREX Quantum) offer thematic exposure — crypto, autonomous vehicles, quantum connectivity — wrapped in significant execution and dilution risk.

With Armlogi’s earnings landing within days and Nuwellis’s pediatric FDA submission window opening this month, expect this list’s volatility to stay elevated through the rest of September — precisely the kind of environment where sub-$1 stocks can move 20%, 50%, or more in a single session on genuinely new information.

At a Glance: Top 10 Stocks Under $1 to Watch

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. Stocks trading under $1 carry extreme risk, including thin liquidity, heavy historical shareholder dilution, wide bid-ask spreads, and elevated volatility — losses can occur rapidly and in full. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change, sometimes dramatically, within a single trading session. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence and consider consulting a licensed financial advisor prior to executing any penny stock trades.

About The Author

Kasia Davis

See author's posts